Astellas Partnership - Major asset | VICL Message Board Posts

VICL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3400 of 3410  at  6/8/2016 4:04:00 PM  by

erasmus


Astellas Partnership - Major asset

 

Vical Provides VL-2397 Updates at BIO International Convention

VL-2397 was initially developed by Astellas Pharma Inc. (TOKYO: 4503). In March 2015, Astellas granted Vical an exclusive worldwide license to develop and commercialize VL-2397.

Full text Vical site:

http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Provides-VL-2397-Updates-at-BIO-International-Convention/default.aspx

Astellas partnership is what makes Vical attractive:

See also pipeline, Astellas is involved in two advanced trials phase II and phase III, see link:

http://www.vical.com/products/pipeline/default.aspx



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 950
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
3401 Re: Astellas Partnership - Pioneer in Antifungal drugs erasmus 1 6/9/2016 2:11:17 AM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...